FI3920891T3 - Nopeasti hajoavat kannabinoiditabletit - Google Patents
Nopeasti hajoavat kannabinoiditabletit Download PDFInfo
- Publication number
- FI3920891T3 FI3920891T3 FIEP20727578.5T FI20727578T FI3920891T3 FI 3920891 T3 FI3920891 T3 FI 3920891T3 FI 20727578 T FI20727578 T FI 20727578T FI 3920891 T3 FI3920891 T3 FI 3920891T3
- Authority
- FI
- Finland
- Prior art keywords
- tablet
- tablet according
- cannabinoids
- sugar alcohol
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3040513A CA3040513C (en) | 2019-04-17 | 2019-04-17 | An oral cannabinoid tablet |
| CA3040547A CA3040547C (en) | 2019-04-17 | 2019-04-17 | Cannabinoid lozenge formulation |
| CA3040532A CA3040532C (en) | 2019-04-17 | 2019-04-17 | Lozenge for improved delivery of cannabinoids |
| US16/386,477 US10925853B2 (en) | 2019-04-17 | 2019-04-17 | Oral cannabinoid tablet |
| CA3065042A CA3065042C (en) | 2019-12-13 | 2019-12-13 | Fast disintegrating cannabinoid tablets |
| US16/713,580 US11633351B2 (en) | 2019-12-13 | 2019-12-13 | Fast disintegrating cannabinoid tablets |
| PCT/DK2020/050102 WO2020211915A1 (en) | 2019-04-17 | 2020-04-17 | Fast disintegrating cannabinoid tablets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3920891T3 true FI3920891T3 (fi) | 2024-03-19 |
Family
ID=70802555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20727578.5T FI3920891T3 (fi) | 2019-04-17 | 2020-04-17 | Nopeasti hajoavat kannabinoiditabletit |
Country Status (12)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020412501A1 (en) * | 2019-12-24 | 2022-08-18 | Cannadol Pharmaceuticals Ltd | Compositions comprising terpenes and their use in the treatment or alleviation of pain or anxiety |
| TWI923583B (zh) * | 2020-04-14 | 2026-05-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物 |
| LT4243797T (lt) * | 2020-11-16 | 2026-06-10 | Orcosa Inc. | Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui |
| US11672761B2 (en) * | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CN114748429A (zh) * | 2020-12-29 | 2022-07-15 | 汉义生物科技(北京)有限公司 | 一种水溶性大麻素制剂及其制备方法 |
| JP2023010677A (ja) * | 2021-07-09 | 2023-01-20 | 株式会社東洋新薬 | 固形組成物 |
| JP2023010676A (ja) * | 2021-07-09 | 2023-01-20 | 株式会社東洋新薬 | 固形組成物 |
| US20240415853A1 (en) * | 2023-03-21 | 2024-12-19 | Fertin Pharma A/S | Cannabinoid Self-Emulsifying Systems |
| JP2025529608A (ja) * | 2023-07-24 | 2025-09-09 | ポビバ コーポレーション | てんかんを処置する為の組成物及び方法 |
| DK202330231A1 (en) * | 2023-09-27 | 2025-04-10 | Fertin Pharma As | Cannabidiol for alleviating xerostomia |
| CN118021744A (zh) * | 2024-02-05 | 2024-05-14 | 谛邈生物科技(北京)有限公司 | 一种大麻二酚型大麻素化合物冻干闪释片及其制备方法 |
| DK202430722A1 (en) * | 2024-11-25 | 2026-06-09 | Fertin Pharma As | Sugar free soft chew tablets |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1361864T3 (en) * | 2001-02-14 | 2014-03-03 | Gw Pharma Ltd | FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids |
| GB0320854D0 (en) * | 2003-09-05 | 2003-10-08 | Arrow No 7 Ltd | Buccal drug delivery |
| CA2664315C (en) * | 2006-09-15 | 2016-01-19 | Echo Pharmaceuticals B.V. | Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances |
| EP2164462B1 (de) * | 2007-06-06 | 2017-05-31 | Basf Se | Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten |
| US20090004248A1 (en) * | 2007-06-29 | 2009-01-01 | Frank Bunick | Dual portion dosage lozenge form |
| US9023322B2 (en) * | 2008-03-26 | 2015-05-05 | Stichting Sanammad | Chewing gum compositions comprising cannabinoids |
| WO2009151072A1 (ja) * | 2008-06-13 | 2009-12-17 | 大日本住友製薬株式会社 | 口腔内速崩壊錠及びその製造方法 |
| KR20130076015A (ko) * | 2011-12-28 | 2013-07-08 | 주식회사 삼양바이오팜 | 높은 경도를 갖는 속붕정 및 이의 제조 방법 |
| EP2609912A1 (en) * | 2011-12-30 | 2013-07-03 | Deva Holding Anonim Sirketi | Pharmaceutical combination of fingolimod and nabiximols |
| CA2845443A1 (en) * | 2014-03-04 | 2015-09-04 | Pharmascience Inc. | Orally disintegrating tablet of nabilone and method of manufacturing |
| CA2992923C (en) * | 2014-07-21 | 2021-06-29 | Pharmaceutical Productions, Inc. | Solid dosage form composition for buccal and sublingual administration of cannabinoids |
| WO2016092539A1 (en) * | 2014-12-07 | 2016-06-16 | One World Cannabis Ltd | Use of cannabis to treat migraine |
| EP3253368A4 (en) * | 2015-02-02 | 2018-08-22 | Axim Biotechnologies, Inc. | Cannabinoid and sugar alcohol complex, methods to make and use |
| US10765658B2 (en) * | 2016-06-22 | 2020-09-08 | Mastix LLC | Oral compositions delivering therapeutically effective amounts of cannabinoids |
| KR20220132674A (ko) * | 2016-08-03 | 2022-09-30 | 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 | 카나비스 조성물 |
| CA3052564A1 (en) * | 2017-02-05 | 2018-08-09 | CannTab Therapeutics Limited | Flash-melt cannabinoid formulations |
| US10772837B2 (en) * | 2017-03-16 | 2020-09-15 | CannTab Therapeutics, Ltd | Modified release multi-layer tablet cannabinoid formulations |
| JP2020520966A (ja) * | 2017-05-22 | 2020-07-16 | ジービーエス グローバル バイオファーマ,インコーポレイテッド | Trpv1を標的にするミルセン及びカンナビノイド含有組成物 |
| JP2021513566A (ja) * | 2018-02-09 | 2021-05-27 | ニュートリスキ インターナショナル インク.Neutrisci International Inc. | スチルベノイドとカンナビノイドとの共結晶を含む組成物 |
-
2020
- 2020-04-17 CN CN202080029225.3A patent/CN113784704A/zh active Pending
- 2020-04-17 BR BR112021020523A patent/BR112021020523A2/pt unknown
- 2020-04-17 AU AU2020258631A patent/AU2020258631B2/en active Active
- 2020-04-17 FI FIEP20727578.5T patent/FI3920891T3/fi active
- 2020-04-17 EP EP23196168.1A patent/EP4268815A3/en active Pending
- 2020-04-17 PL PL20727578.5T patent/PL3920891T3/pl unknown
- 2020-04-17 JP JP2021561780A patent/JP7556882B2/ja active Active
- 2020-04-17 WO PCT/DK2020/050102 patent/WO2020211915A1/en not_active Ceased
- 2020-04-17 DK DK20727578.5T patent/DK3920891T3/da active
- 2020-04-17 EP EP20727578.5A patent/EP3920891B1/en active Active
- 2020-04-17 MX MX2021012712A patent/MX2021012712A/es unknown
- 2020-04-17 ES ES20727578T patent/ES2975266T3/es active Active
-
2021
- 2021-09-30 ZA ZA2021/07389A patent/ZA202107389B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021012712A (es) | 2021-11-12 |
| BR112021020523A2 (pt) | 2021-12-07 |
| JP7556882B2 (ja) | 2024-09-26 |
| EP4268815A3 (en) | 2024-02-21 |
| EP3920891B1 (en) | 2024-02-21 |
| ZA202107389B (en) | 2025-04-30 |
| CN113784704A (zh) | 2021-12-10 |
| PL3920891T3 (pl) | 2024-05-20 |
| ES2975266T3 (es) | 2024-07-04 |
| EP4268815A2 (en) | 2023-11-01 |
| AU2020258631B2 (en) | 2023-11-02 |
| AU2020258631A1 (en) | 2021-10-28 |
| DK3920891T3 (da) | 2024-03-18 |
| JP2022529037A (ja) | 2022-06-16 |
| WO2020211915A1 (en) | 2020-10-22 |
| EP3920891A1 (en) | 2021-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529037A5 (cg-RX-API-DMAC10.html) | ||
| Ko et al. | Flavonoids as therapeutic candidates for emotional disorders such as anxiety and depression: Y.-H. Ko et al. | |
| CA2703698C (en) | Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent | |
| Matsui et al. | α-Glucosidase inhibitory profile of catechins and theaflavins | |
| Zaklos-Szyda et al. | Antidiabetic effect of polyphenolic extracts from selected edible plants as α-amylase, α-glucosidase and PTP1B inhibitors, and β pancreatic cells cytoprotective agents-a comparative study | |
| CA2636634C (en) | Cannabinoid-containing plant extracts as neuroprotective agents | |
| US20180235917A1 (en) | Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia | |
| AU2017341707A1 (en) | An oral composition of extracted cannabinoids and methods of use thereof | |
| Wang | Natural plant resource flavonoids as potential therapeutic drugs for pulmonary fibrosis | |
| WO2020018845A1 (en) | Rapidly dissolving pharmaceutical compositions and method of manufacturing | |
| Liu et al. | Cytotoxic and antioxidant effects of the water extract of the traditional Chinese herb gusuibu (Drynaria fortunei) on rat osteoblasts | |
| AU2020258631A1 (en) | Fast disintegrating cannabinoid tablets | |
| US20040071685A1 (en) | Compositions and methods for increasing the bioavailability of plant polyphenols | |
| EP3955897A1 (en) | Cannabinoid lozenge formulation | |
| US6524630B2 (en) | Use of cocoa procyanidins combined with acelylsalicyclic acid as an anti-platelet therapy | |
| Goswami et al. | Flavonoids, isoflavonoids and others bioactives for insulin sensitizations | |
| Makowczynska et al. | Antioxidant activity of tissue culture-raised Ballota nigra L. plants grown ex vitro | |
| Prada et al. | Development, pharmacological and toxicological evaluation of a new tablet formulation based on Cassia grandis fruit extract | |
| AU2001261004A1 (en) | The use of cocoa procyanidins combined with acetylsalicyclic acid as an anti-platelet therapy | |
| US12220397B2 (en) | Brain health formulation | |
| JP2010043035A (ja) | サラシア属植物を含有する経口用組成物 | |
| Sa-Ngiamsuntorn et al. | Hepatoprotective effects of Acanthopanax trifoliatus standardized leaf extract and its formulations in a HepG2 model | |
| Fang et al. | β‐Secretase (BACE1) inhibitors from natural products | |
| ES3064715T3 (en) | Powdered composition of mint oil extract and amaranth seeds flour | |
| Nawangsari et al. | Piper betel L. Leaf Extract Lozenges for Preventing Dental Caries for Children |